Efficacy of trimetazidine and its influence upon metabolic processes in patients with ischemic heart disease
Article Sidebar
Main Article Content
Abstract
The aim – to examine the effectiveness of the trimetazidine and its metabolic influences in patients with ischemic heart disease.
Material and methods. The pilot study was conducted in 10 patients (6 women and 4 men) aged 49–80 years with stable angina pectoris I–III functional class NYHA. All patients were examined at baseline and after 1 month of therapy with trimetazidine 35 mg twice daily.
Results. After 1 month of therapy with trimetazidine we noted decreased number of angina attacks by 2.39 times and reduce of their duration by 2.32 times. We also observed decrease in index-induced apoptosis, normalization of lipid peroxidation (malondialdehyde reducing and increasing antioxidant status), increase of HDL cholesterol, lower levels of uric acid and C-reactive protein.
Conclusions. These data show clinical efficacy of trimetazidine and its positive effects upon metabolic processes.
Article Details
Keywords:
References
Методичні рекомендації щодо лікування стабільної стенокардії Асоціації кардіологів України.– К., 2016.
Стабільна ішемічна хвороба серця. Адаптована клінічна настанова, заснована на доказах // Реєстр медико-технологічних документів.– 2016.– URL: http://mtd.dec.gov.ua/images/dodatki/2016_152_IHS/2016_152_AKN_IHS.pdf
Di Napoli P., Taccardi A.A., Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy // Heart.– 2005.– Vol. 91.– P. 161–165.
Fragasso G., Perseghin G., De Cobelli F. et al. Effects of metabolic modulation by trimetazidine on left ventricular function an phosphocreatine / adenosine triphopshate ratio in patients with heart failure // Eur. Heart. J.– 2006.– Vol. 27.– P. 942–948.
Génissel P., Chodjania Y., Demolis J.L. et al. Assessment of the sustained release properties of a new oral formulation of trimetazidine in pigs and dogs and confirmation in healthy human volunteers // Eur. J. Drug Metab. Pharmacokinet.– 2004.– Vol. 29 (1).– Р. 61–68.
Kantor P.F., Lucien A., Kozak R. et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase // J. Circ. Res.– 2000.– Vol. 86 (5).– P. 580–588.
Lee L., Horowitz J., Frenneaux M. Metabolic manipulation in ischaemicheart disease, a novel approach to treatment // Eur. Heart J.– 2004.– Vol. 25.– P. 634–641.
Stanley W.C., Lopaschuk G.D., Hall J.L., McCormack J.G. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions // Cardiovasc. Res.– 1997.– Vol. 33.– P. 243–257.
Vande Werf F., Bax J., Betriu A. et al. ESC Committeefor Practice Guidelines (CPG). Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Forceon the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology // Eur. Heart J.– 2008.– Vol. 29 (23).– P. 2909–2945.
ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease // Circulation.– 2012.– 18/25.
ESC guidelines on the management of stable coronary artery disease.– Eur Heart J.– 2013.